Parecoxib
is a water-soluble and injectable prodrug of valdecoxib. It is marketed as
Dynastat in the European Union. Parecoxib is a COX2 careful inhibitor in the
aforementioned class as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is
injectable, it can be used perioperatively if patients are clumsy to yield
articulate medications. It is accustomed through abundant of Europe for
abbreviate appellation perioperative affliction ascendancy abundant in the
aforementioned way ketorolac (Toradol) is used in the United States. In 2005,
the U.S. Food and Biologic Administering (FDA) issued a letter of non-approval
for parecoxib in the United States.
Parecoxib
is an amide prodrug of the cyclooxygenase II (COX-2) selective, non-steroidal
anti-inflammatory biologic (NSAID) valdecoxib, with anti-inflammatory,
analgesic, and antipyretic activities. Upon administration, parecoxib is hydrolyzed
by hepatic carboxyesterases to its active form, valdecoxib. Valdecoxib
selectively binds to and inhibits COX-2. This prevents the about-face of
arachidonic acid into prostaglandins, which are complex in the adjustment of
pain, inflammation, and fever. This NSAID does not arrest COX-1 at ameliorative
concentrations and, therefore, does not baffle with blood coagulation.